Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition

References

• Graham JR. Gastric polyposis: onset during long-term therapy with omeprazole. Med J Aust 1992; 157: 287–8
   PubMed Web of Science ®Google Scholar
• Graham JR. Omeprazole and gastric polyposis in humans. Gastroenterology 1993; 104: 1584
   PubMed Web of Science ®Google Scholar
• Jalving M, Koornstra JJ, Wesseling J, Boezen HM, Jong S DE, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1341–8
   PubMed Web of Science ®Google Scholar
• Choudhry U, Boyce HW, Jr, Coppola D. Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. Am J Clin Pathol 1998; 110: 615–21
   PubMed Web of Science ®Google Scholar
• Torbenson M, Lee JH, Cruz-Correa M, Ravich W, Rastgar K, Abraham SC, et al. Sporadic fundic gland polyposis: a clinical, histological, and molecular analysis. Mod Pathol 2002; 15: 718–23
   PubMed Web of Science ®Google Scholar
• Wu TT, Kornacki S, Rashid A, Yardley JH, Hamilton SR. Dysplasia and dysregulation of proliferation in foveolar and surface epithelia of fundic gland polyps from patients with familial adenomatous polyposis. Am J Surg Pathol 1998; 22: 293–8
   PubMed Web of Science ®Google Scholar
• Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 1998; 85: 742–50
   PubMed Web of Science ®Google Scholar
• Zwick A, Munir M, Ryan CK, Gian J, Burt RW, Leppert M, et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997; 113: 659–63
   PubMed Web of Science ®Google Scholar
• Flick AL. Gastric fundal polyps with cellular atypia in a patient using esomeprazole (Nexium). Dig Dis Sci 2005; 50: 2100–2
   PubMed Web of Science ®Google Scholar
• Larsson H, Carlsson E, Mattsson H, Lundell L, Sundler F, Sundell G, et al. Plasma gastrin and gastric enterochromaffinlike cell activation and proliferation. Studies with omeprazole and ranitidine in intact and antrectomized rats. Gastroenterology 1986; 90: 391–9
   PubMed Web of Science ®Google Scholar
• Havu N. Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric secretion. Digestion 1986; 35 Suppl 1: 42–55
   PubMed Web of Science ®Google Scholar
• Klinkenberg-Knol EC, Festen HP, Jansen JB, Lamers CB, Nelis F, Snel P, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161–7
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. FDA background. Omeprazole magensium (Prilosec 1 TM) Astra Zeneca with Proctor and Gamble. For the Joint Meeting of the Nonprescription Drugs Advisory Committee and the Gastrointestinal Drugs Advisory Committee on October 20, 2000.
   Google Scholar
• Qvigstad G, Qvigstad T, Westre B, Sandvik AK, Brenna E, Waldum HL. Neuroendocrine differentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 2002; 110: 132–9
   PubMed Web of Science ®Google Scholar
• Waldum HL, Aase S, Kvetnoi I, Brenna E, Sandvik AK, Syversen U, et al. Neuroendocrine differentiation in human gastric carcinoma. Cancer 1998; 83: 435–44
   PubMed Web of Science ®Google Scholar
• Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK. Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 1996; 39: 649–53
   PubMed Web of Science ®Google Scholar
• el-Zimaity HM, Jackson FW, Graham DY. Fundic gland polyps developing during omeprazole therapy. Am J Gastroenterol 1997; 92: 1858–60
   PubMed Web of Science ®Google Scholar
• Waldum HL, Sandvik AK, Brenna E, Petersen H. Gastrin-histamine sequence in the regulation of gastric acid secretion. Gut 1991; 32: 698–701
   PubMed Web of Science ®Google Scholar
• Fossmark R, Johnsen G, Johanessen E, Waldum HL. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21: 149–54
   PubMed Web of Science ®Google Scholar
• Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985; 20: 569–76
   PubMed Web of Science ®Google Scholar
• Syversen U, Jacobsen MB, O'Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994; 26: 201–6
   PubMed Web of Science ®Google Scholar
• Waldum HL, Brenna E, Sandvik AK, Petersen H. Trophic effect of histamine on the stomach. Scand J Gastroenterol 1991; Suppl 180: 137–42
   Web of Science ®Google Scholar
• Watson SA, Wilkinson LJ, Robertson JF, Hardcastle JD. Effect of histamine on the growth of human gastrointestinal tumours: reversal by cimetidine. Gut 1993; 34: 1091–6
   PubMed Web of Science ®Google Scholar
• Fukui H, Kinoshita Y, Maekawa T, Okada A, Waki S, Hassan S, et al. Regenerating gene protein may mediate gastric mucosal proliferation induced by hypergastrinemia in rats. Gastroenterology 1998; 115: 1483–93
   PubMed Web of Science ®Google Scholar
• Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?. Am J Gastroenterol 2004; 99: 23–32
   PubMed Web of Science ®Google Scholar
• Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM, Pritchard DM, et al. Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor. Gastroenterology 2003; 124: 615–25
   PubMed Web of Science ®Google Scholar
• Smith JT, Pounder RE, Nwokolo CU, Lanzon-Miller S, Evans DG, Graham DY, et al. Inappropriate hypergastrinaemia in asymptomatic healthy subjects infected with Helicobacter pylori. Gut 1990; 31: 522–5
   PubMed Web of Science ®Google Scholar
• Håkanson R, Ding XQ, Norlen P, Chen D. Circulating pancreastatin is a marker for the enterochromaffin-like cells of the rat stomach. Gastroenterology 1995; 108: 1445–52
   PubMed Web of Science ®Google Scholar
• Sanduleanu S, De Bruine A, Stridsberg M, Jonkers D, Biemond I, Hameeteman W, et al. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy. Eur J Clin Invest 2001; 31: 802–11
   PubMed Web of Science ®Google Scholar